


Express Mail Label: EJ770265105US

Date of Deposit: February 1, 2002

JC07 PCT/PTO 01 FEB 2002  
Attorney Docket No.: 24356-001 NATL (BSW-1 NATL)

pat

#5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Slater and Barden  
APPLICATION NO. : 10/019,356  
EXAMINER : Not Yet Assigned  
§371 FILING DATE : October 22, 2001  
ART UNIT : Not Yet Assigned  
FOR : A Method for Identifying Pre-Neoplastic and/or Neoplastic States in Mammals

**BOX IDS**

Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:


1. Information Disclosure Statement (2 pages);
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References B1 and C1-C4; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

No fee is believed to be due. However, if necessary, the Commissioner is authorized to charge any underpayment, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24356-001 NATL (BSW-1 NATL). A duplicate copy of this transmittal letter is enclosed herewith.

Nicholas P. Triano III, Reg. No. 36,397  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and  
POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: February 1, 2002



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Slater and Barden

APPLICATION NO: 10/019,356

EXAMINER: Not Yet Assigned

§371 FILING DATE: October 22, 2001

ART UNIT: Not Yet Assigned

FOR: A Method for Identifying Pre-Neoplastic and/or Neoplastic States in Mammals

**BOX IDS**

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, full copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Applicants respectfully request that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the PATENT AND TRADEMARK OFFICE during the examination of this application.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits

issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 50-0311 (Reference No. 24356-001 NATL (BSW-1 NATL)).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Nicholas P. Triano III", is written over a horizontal line.

Nicholas P. Triano III, Reg. No. 36,397  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and  
POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: February 1, 2002

TRA 1625048v1

Please type a plus sign (+) in this box



Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/019,356
	<b>Filing Date</b>	10/22/01
	<b>First Named Inventor</b>	Slater
	<b>Group Art Unit</b>	Not Yet Assigned
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	24356-001 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	98/42835	Otsuka Pharmaceutical Co. LTD	October 1, 1998		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Hopfner et al. (1998). <i>Biochem and Biophys Res Comm</i> 251: 811-817.					
	C2	Nawa et al. (1999). <i>British J. of Cancer</i> 80: 1185-1189.					
	C3	Urano et al. (1997). <i>Cancer Research</i> 57: 3281-3287.					
	C4	Wurl et al. (1998). <i>Oncogene</i> 16: 1183-1185.					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1624516v1

TRA 1622056v1